gemcitabine

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor

Related drugs:

‹

›

TRPV6 overexpression	Pancreatic Cancer	TRPV6 overexpression	Pancreatic Cancer	gemcitabine Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) gemcitabine Resistant : C3 AACR 2023 - 2wk	gemcitabine Resistant: C3 – Early Trials AACR 2023 - 2 weeks gemcitabine Resistant : C3 AACR 2023 - 2 weeks - (New C3)
USP42 mutation	Pancreatic Cancer	USP42 mutation	Pancreatic Cancer	gemcitabine Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) gemcitabine Resistant : C3 AACR 2023 - 2wk	gemcitabine Resistant: C3 – Early Trials AACR 2023 - 2 weeks gemcitabine Resistant : C3 AACR 2023 - 2 weeks - (New C3)
MUC13 overexpression	Pancreatic Cancer	MUC13 overexpression	Pancreatic Cancer	gemcitabine Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) gemcitabine Resistant : C3 AACR 2023 - 2wk	gemcitabine Resistant: C3 – Early Trials AACR 2023 - 2 weeks gemcitabine Resistant : C3 AACR 2023 - 2 weeks - (New C3)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1
No biomarker	Small Intestinal Carcinoma	No biomarker	Small Intestinal Carcinoma	docetaxel + gemcitabine Sensitive: A2 - Guideline docetaxel + gemcitabine Sensitive : A2	docetaxel + gemcitabine Sensitive: A2 - Guideline docetaxel + gemcitabine Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Small Intestinal Carcinoma	No biomarker	Small Intestinal Carcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	docetaxel + gemcitabine Sensitive: A2 - Guideline docetaxel + gemcitabine Sensitive : A2	docetaxel + gemcitabine Sensitive: A2 - Guideline docetaxel + gemcitabine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	gemcitabine + vinorelbine tartrate Sensitive: A2 - Guideline gemcitabine + vinorelbine tartrate Sensitive : A2	gemcitabine + vinorelbine tartrate Sensitive: A2 - Guideline gemcitabine + vinorelbine tartrate Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2
BRCA1 mutation	Pancreatic Adenocarcinoma	BRCA1 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
BRCA2 mutation	Pancreatic Adenocarcinoma	BRCA2 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
No biomarker	Small Intestinal Carcinoma	No biomarker	Small Intestinal Carcinoma	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	paclitaxel + gemcitabine + oxaliplatin Sensitive: A2 - Guideline paclitaxel + gemcitabine + oxaliplatin Sensitive : A2	paclitaxel + gemcitabine + oxaliplatin Sensitive: A2 - Guideline paclitaxel + gemcitabine + oxaliplatin Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2

gemcitabine

Associations
(155)

Associations
(155)

gemcitabine

Associations(155)

Associations(155)

Associations
(155)

Associations
(155)